US startup Covenant to launch cruise missile production in Germany next year

U.S. defense startup Covenant plans to begin German mass production of its Europe-sourced Anthem cruise missile in early 2027, targeting a production run rate of 5,000 units in 2028. The company has secured one European contract and is pursuing further orders as European states seek lower-cost, U.S.-independent long-range weapons amid perceived Russian threats. Anthem carries a payload exceeding 200 kg and is positioned as a more affordable alternative to Raytheon’s Tomahawk, while Europe’s missile demand could reach tens of thousands of units.

Analysis

Covenant is not investable, and its 2027 delivery schedule makes its near-term effect on listed defense earnings negligible. The market implication is instead a procurement shift: European buyers are increasingly assigning value to sovereign supply chains, recurring munition availability, and production throughput rather than solely platform performance. That favors Rheinmetall (RHM.DE), Kongsberg Gruppen (KOG.OL), Saab (SAAB-B.ST), Leonardo (LDO.IM), and Hensoldt (HAG.DE), particularly suppliers with European-qualified propulsion, guidance, electronics, and energetic-material capacity.

RTX faces a nuanced read-through. A larger European long-range strike market remains positive for missile demand overall, but a requirement for non-U.S. content can reduce RTX's addressable share in European replenishment tenders and pressure the strategic premium attached to Tomahawk exports. The more material risk is not unit-price competition; it is that lower-cost European systems reset procurement expectations toward affordable mass, potentially favoring local producers with shorter contracting and export-approval paths over high-end U.S. systems.

Over the next 1-3 months, watch German and Nordic defense-budget implementation, long-range strike tenders, and any European Union funding vehicle that explicitly rewards domestic content. Over 6-18 months, bottlenecks in rocket motors, explosives, seekers, and test capacity should create pricing power for incumbent European subsystem providers; a startup's stated run-rate is not evidence that these bottlenecks are solved. The contrarian view is that the listed European primes may already discount substantial rearmament: absent funded orders, Covenant's announcement is more evidence of demand urgency than an earnings catalyst.

The thesis is falsified if European procurement continues to prioritize interoperability with U.S. launch systems and munitions, or if ceasefire/detente materially reduces multi-year replenishment commitments. For RTX specifically, a stronger-than-expected international missile backlog or evidence that its European sourcing footprint meets sovereignty requirements would negate the relative-underweight case.

Key Decisions for Investors

• Maintain a 6-18 month overweight in European defense exposure via RHM.DE, KOG.OL, SAAB-B.ST, and LDO.IM; favor names with consumables and missile/subsystem exposure over platform-heavy defense. Add only on funded-order announcements or 10-15% drawdowns, given elevated rearmament expectations.
• Use a relative watch trade: long a basket of RHM.DE/KOG.OL/SAAB-B.ST versus RTX over the next 3-6 months if European tenders contain explicit local-content or U.S.-component restrictions. Exit if RTX discloses comparable European-qualified production or wins the relevant procurement awards.
• Do not short RTX outright on this development: its U.S. and allied replenishment demand can offset European share risk. Reassess a relative underweight only if European long-range strike awards visibly migrate to domestic suppliers and RTX's international missile-booking commentary weakens.
• Set an event alert for German budget releases, EU defense-industrial funding, and missile procurement tenders before initiating additional exposure. The missing decision-critical data are contract values, covenant production financing, European component qualification, and the economics of local incumbent suppliers.